Keymed Biosciences Inc. (HKG: 2162) announced that the Phase 2 trial of CM512 injection, a Category 1 innovative drug independently developed by the Company for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP), has completed data unblinding and preliminary statistical analysis, achieving all study endpoints.
Trial Milestone Overview
Item
Detail
Sponsor
Keymed Biosciences Inc. (HKG: 2162)
Product
CM512 injection (Category 1 innovative drug)
Indication
Chronic rhinosinusitis with nasal polyps (CRSwNP)
Trial Stage
Phase 2
Outcome
Data unblinding completed; all study endpoints achieved
World’s first long‑acting IgG‑like TSLP × IL‑13 dual blocker
Regulatory Status
Granted Breakthrough Therapy Designation by the Center for Drug Evaluation (CDE) of China’s NMPA for CRSwNP
Phase 2 Efficacy Results
Dimension
Result
Dose Response
Comparable efficacy across all dosage groups
Nasal Polyp Size
Rapid reduction in nasal polyp size
Nasal Congestion
Significant improvement as early as Week 4 after administration
Olfactory Function
Facilitated recovery of olfactory function
Durability
Efficacy of a single dose sustained for half a year
NPS at Week 24
Change from baseline in nasal polyp score (NPS) significantly superior to the control group
Sinus Inflammation
Significantly alleviated overall inflammation in the sinus cavities
Safety Profile
Dimension
Result
Safety & Tolerability
Favorable profiles across all dosage groups
Anti‑Drug Antibodies (ADA)
Extremely low incidence
Treatment‑Emergent Adverse Events (TEAEs)
Incidence comparable to the placebo group
Serious Adverse Events
None reported
Phase 3 Plans
Keymed Biosciences is rapidly initiating the Phase 3 trial of CM512 for the treatment of CRSwNP, with a confirmed dosing regimen of 300 mg every 24 weeks (Q24W) — a twice‑yearly schedule that could be a major compliance advantage in chronic disease management.
Strategic Rationale & Market Impact
First‑in‑Class Dual Blockade: As the world’s first long‑acting IgG‑like TSLP × IL‑13 dual blocker, CM512 simultaneously targets two key upstream drivers of type 2 inflammation — a differentiated mechanism versus single‑target biologics in CRSwNP.
Six‑Month Durability: Single‑dose efficacy sustained for half a year supports the Q24W dosing regimen, a potentially best‑in‑class convenience profile that could drive adherence and market adoption.
Clean Safety Readout: TEAE incidence comparable to placebo, no serious adverse events, and an extremely low ADA rate strengthen CM512’s positioning in a chronic indication where long‑term tolerability is decisive.
Regulatory Momentum:Breakthrough Therapy Designation from China’s CDE, combined with a clean Phase 2 readout and an already‑confirmed Phase 3 regimen, gives Keymed a fast‑track trajectory toward potential registration.
Forward‑Looking Statements This brief contains forward‑looking statements regarding CM512’s Phase 3 development, regulatory outcomes, and commercial potential. Actual results may differ due to risks including clinical trial results, regulatory decisions, and competitive dynamics.-Fineline Info & Tech
By Fineline Cube